Loading stock data…
$0.41-0.02 (-5.66%)
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
Moleculin Biotech, Inc. in the Healthcare sector is trading at $0.41 with a market capitalization of $15M. Wall Street consensus targets $12.00 (3 analysts), implying a +2822.6% move over the next 12 months. The stock is currently near its 52-week low of $0.16, remaining 81.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.56M↑ | -$7.87M↓ | -$7.53M↓ | -$5.91M↓ | -$5.72M |
| Net Income | -$7.63M↑ | -$12.85M↓ | $15.55M↑ | -$25.40M↓ | -$17.81M |
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage...